What is the Share Price of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd share price is ₹1,162.70 As on 19 September, 2024|10:27

Home
>
Stocks
>
Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd

Q: What is the Market Cap of Alembic Pharmaceuticals Ltd?

The Market Cap of Alembic Pharmaceuticals Ltd is ₹23,377 As on 19 September, 2024|10:27

Q: What is PE Ratio of Alembic Pharmaceuticals Ltd?

The P/E ratio of Alembic Pharmaceuticals Ltd is 37.1 As on 19 September, 2024|10:27

Q: What is PB Ratio of Alembic Pharmaceuticals Ltd?

The PB ratio of Alembic Pharmaceuticals Ltd is 4.75 As on 19 September, 2024|10:27

₹ 1,162.70 -26.60 (-2.24%)
Updated on 19-09-2024 10:27 AM

Stock Rating

Pros 3

Cons 3

Price Performance

Day's Low
₹1,158.10

Day's High
₹1,195.60

₹ 1,162.70

52-w low
₹707.15

52-w high
₹1,284.95

1,162.70

Day's open
₹1,185
Previous close
₹1,189.30
VWAP
₹1,174.27
Lower price band
₹951.45
Upper price band
₹1,427.15

Today's Market Action

The last traded share price of Alembic Pharmaceuticals Ltd was 1,162.70 down by -2.24% on the NSE. Its last traded stock price on BSE was 1,161.80 down by -2.27%. The total volume of shares on NSE and BSE combined was 54,053 shares. Its total combined turnover was Rs 6.35 crores.

Medium and Long Term Market Action

Alembic Pharmaceuticals Ltd hit a 52-week high of 1,284.95 on 08-08-2024 and a 52-week low of 707.15 on 31-10-2023. The stock price of Alembic Pharmaceuticals Ltd is up by 10% over the last one month. It is up by 48.5% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

Market Cap (Cr): 23377
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About

Data not available.

FAQ's

What is Share Price of Alembic Pharmaceuticals Ltd?

What is the Market Cap of Alembic Pharmaceuticals Ltd?

What is PE Ratio of Alembic Pharmaceuticals Ltd?

What is PB Ratio of Alembic Pharmaceuticals Ltd?

What is the CAGR of Alembic Pharmaceuticals Ltd?

How to Buy Alembic Pharmaceuticals Ltd Share?

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

Momentum Strength
The stock is currently exhibiting strong momentum, & is showing consistent strong relative strength.
Above Average Sustainable RoE
The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
Great Cash Conversion of Profits
The business has a great cash conversion ratio since it is able to convert a signifant portion of operating earnings of 83.56% into operating cash flow. This implies a great working capital cycle and large cash flows for either funding growth or dividends. This shall positively impact shareholder returns.

Cons

Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Capital Intensive Business
The company operates an extremely capital intensive business with a low Asset turnover ratio of 1.99. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 159 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(19/09/2024)

Margin of Safety Index: High

84.21%

84.21% People are bullish about Alembic Pharmaceuticals Ltd

15.79%

15.79 % People are bearish about Alembic Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %